Eviplera is a single-tablet antiretroviral medication combining rilpivirine, emtricitabine, and tenofovir disoproxil to treat HIV-1. It works by blocking the reverse transcriptase enzyme, which prevents the virus from replicating and infecting new cells, effectively lowering the viral load in the bloodstream.
- Triple-action formula: Contains three active substances targeting the same essential viral enzyme.
- Viral suppression: Reduces HIV levels to help CD4+ T cells recover.
- Daily regimen: Requires one tablet taken daily specifically with a full meal.
- Eligibility criteria: Designed for adults with viral loads under 100,000 copies/mL.
Bookimed Expert Insight: While Eviplera is highly effective, its rilpivirine component has a lower barrier to resistance than newer integrase inhibitors. Patients in Turkey often work with specialists like Associate Professor Husrev Diktas at Medipol Acibadem, who prioritize resistance genotyping before starting this specific regimen to ensure long-term success.
Patient Consensus: Many patients report vivid dreams or insomnia during the first month, though these effects typically fade. Consistency is vital, as missing doses with this specific drug combination significantly increases the risk of treatment resistance.